851916-84-2

Basic information

• Product Name: IMidazo[1,2-a]pyridine, 6-broMo-2-chloro-
• Synonyms: IMidazo[1,2-a]pyridine, 6-broMo-2-chloro-
• CAS NO: 851916-84-2
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231.47706
• Mol File: 851916-84-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: IMidazo[1,2-a]pyridine, 6-broMo-2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine, 6-broMo-2-chloro-(851916-84-2)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine, 6-broMo-2-chloro-(851916-84-2)

Safety Data

• Hazardous Substances Data: 851916-84-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine, 6-bromo-2-chlorois utilized as a chemical intermediate for the development of pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of various drug molecules, potentially leading to the creation of new medications with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic chemistry, Imidazo[1,2-a]pyridine, 6-bromo-2-chloroserves as a building block for the synthesis of complex organic compounds. Its presence in these compounds can contribute to the development of new materials with specialized characteristics for different applications.
Used in Research and Development:
IMidazo[1,2-a]pyridine, 6-broMo-2-chlorois also employed in research and development settings to study the properties and behavior of imidazopyridines. Understanding its reactivity, binding affinity, and other attributes can facilitate the discovery of new chemical reactions and the design of novel molecules with desired properties.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 79-11-8 chloroacetic acid 
• 1256037-96-3 C₇H₇BrN₂O₂ 
• 886436-47-1 6-bromo-imidazo[1,2-a]pyridin-2-one 

Downstream Products

• 1187820-68-3 [3-(2-chloroimidazo[1,2-a]pyridin-6-yl)phenyl]methanol 
• 1187820-69-4 [3-[2-(quinolin-3-yl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol 
• 1256033-74-5 N-(3-(3-(4-amino-6-methyl-1,3,5-triazin-2-yl)-2-(1H-pyrazol-3-ylamino)imidazo[1,2-a]pyridin-6-yl)phenyl)acetamide 
• 1256033-62-1 3-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-(2-fluorophenyl)-N-1H-pyrazol-3-ylimidazo[1,2-a]pyridin-2-amine 
• 1256034-21-5 3-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-(3-fluorophenyl)-N-1H-pyrazol-3-ylimidazo[1,2-a]pyridin-2-amine 
• 1256033-63-2 3-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-(2-methylphenyl)-N-1H-pyrazol-3-ylimidazo[1,2-a]pyridin-2-amine 
• 1256037-99-6 C₁₇H₁₂ClFN₆ 
• 1187820-75-2 6-[3-[(tert-butyldimethylsilanyloxy)methyl]phenyl]-2-(1H-indol-6-yl)imidazo[1,2-a]pyridine 
• 1187820-74-1 6-[3-[(tert-butyldimethylsilanyloxy)methyl]phenyl]-2-chloroimidazo[1,2-a]pyridine 
• 1187820-76-3 {3-[2-(1H-indol-6-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}methanol 

Relevant articles and documents

CONTROL METHOD FOR HARMFUL ARTHROPOD USING HETEROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a control method for harmful arthropod. SOLUTION: A control method for harmful arthropod includes a process of applying the effective dose of a composition containing, for example, a compound of below-mentioned formula, or an N-oxide or agriculturally-acceptable salt thereof and one or more components selected from the group consisting of the below-mentioned group (a) to group (j) to the harmful arthropod, habitat thereof, plant or cultivation carrier of the plant. The groups (a) to (j) are as follow: (a): a group comprising insecticidal, mite-killing and nematode-killing active components; (b): disinfect active components; (c): plant growth-controlling components; (d): crop injury-reducing components; (e): synergist; (f): repellent components; (g): mollusk-killing components; (h): insect pheromone; (i): herbicidal active components; and (j): living matter-protective materials. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

METHOD OF CONTROLLING HARMFUL ARTHROPOD USING HETEROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a method of controlling harmful arthropods. SOLUTION: A compound represented by formula (I) or an N oxide thereof can control harmful arthropods [where Q is a group represented by Q1, or a group represented by Q2, Z is an oxygen atom or the like, A2, A3 and A6 each denote a nitrogen atom or the like, A4 is CR1a or the like, A5 is a nitrogen atom or the like, A7 is NR6g or the like, G1, G2, G3 and G4 each denote a nitrogen atom or the like, R1a is a C1-C6 chain hydrocarbon group substituted with one or more substituent selected from the group consisting of a cyano group and a halogen atom, or the like, R2 is a C1-C6 alkyl group optionally substituted with one or more halogen atom, or the like, and n is 0, 1 or 2]. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Pyrrolo-imidazo[1,2- A[pyridine Scaffolds through a Sequential Coupling of N-Tosylhydrazones with Imidazopyridines and Reductive Cadogan Annulation, Synthetic Scope, and Application

A new strategy for the construction of 3-phenyl-1H-pyrrolo-imidazo[1,2-a]pyridine backbone is described. The reaction starts from the coupling between N-tosylhydrazones and 2-chloro-3-nitroimidazo[1,2-a]pyridines leading to the formation of 3-nitro-2-(ary

2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors

Screening of the Amgen compound library led to the identification of 2-phenylamino-6-cyano-1H-benzimidazole 1a as a potent CK1 gamma inhibitor with excellent kinase selectivity and unprecedented CK1 isoform selectivity. Further structure-based optimization of this series resulted in the discovery of 1h which possessed good enzymatic and cellular potency, excellent CK1 isoform and kinase selectivity, and acceptable pharmacokinetic properties.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors

mTOR is a critical regulator of cellular signaling downstream of multiple growth factors. The mTOR/PI3K/AKT pathway is frequently mutated in human cancers and is thus an important oncology target. Herein we report the evolution of our program to discover ATP-competitive mTOR inhibitors that demonstrate improved pharmacokinetic properties and selectivity compared to our previous leads. Through targeted SAR and structure-guided design, new imidazopyridine and imidazopyridazine scaffolds were identified that demonstrated superior inhibition of mTOR in cellular assays, selectivity over the closely related PIKK family and improved in vivo clearance over our previously reported benzimidazole series.

POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF

Compounds of formula (I): wherein R, R1, R2, R3, R4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.